| 9.845 0.505 (5.41%) | 08-11 12:35 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.01 |
1-year : | 14.03 |
| Resists | First : | 10.28 |
Second : | 12.01 |
| Pivot price | 6.3 |
|||
| Supports | First : | 7 |
Second : | 4.98 |
| MAs | MA(5) : | 7.71 |
MA(20) : | 6.28 |
| MA(100) : | 5.24 |
MA(250) : | 4.6 |
|
| MACD | MACD : | 0.4 |
Signal : | 0 |
| %K %D | K(14,3) : | 91.8  |
D(3) : | 89.7 |
| RSI | RSI(14): 79.1 |
|||
| 52-week | High : | 10.28 | Low : | 2.74 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ABCL ] has closed It is unclear right now based on current values. 193.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 10.02 - 10.06 | 10.06 - 10.1 |
| Low: | 8.31 - 8.35 | 8.35 - 8.39 |
| Close: | 9.27 - 9.34 | 9.34 - 9.4 |
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
Tue, 11 Aug 2026
Is AbCellera Biologics (ABCL) Fully Valued After Its 172% Run? - Yahoo Finance
Mon, 10 Aug 2026
AbCellera (ABCL) Rockets 44% as Hot Flash Treatment Brightens Growth Outlook - Yahoo Finance
Mon, 10 Aug 2026
AbCellera stock soars 35% on successful clinical trial result - Business in Vancouver
Mon, 10 Aug 2026
Hot-Flash Drug Trial Result Sends AbCellera Up as Much as 41% - Bloomberg.com
Mon, 10 Aug 2026
AbCellera Stock Jumps 33% on a Positive Menopause Trial - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 305 (M) |
| Shares Float | 205 (M) |
| Held by Insiders | 23 (%) |
| Held by Institutions | 43.1 (%) |
| Shares Short | 45,110 (K) |
| Shares Short P.Month | 44,910 (K) |
| EPS | -0.55 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.22 |
| Profit Margin | -181.8 % |
| Operating Margin | -691.8 % |
| Return on Assets (ttm) | -10 % |
| Return on Equity (ttm) | -14.7 % |
| Qtrly Rev. Growth | 96.3 % |
| Gross Profit (p.s.) | -0.37 |
| Sales Per Share | 0.25 |
| EBITDA (p.s.) | -0.62 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -153 (M) |
| Levered Free Cash Flow | -114 (M) |
| PE Ratio | -18.25 |
| PEG Ratio | 0 |
| Price to Book value | 3.05 |
| Price to Sales | 37.97 |
| Price to Cash Flow | -19.63 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|